
Elacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
from FDA,2023.05
LuciusVersionofElacestrant:DosageandAdministration,Indications,PrecautionsIndicationsElacestrant is ···【more】
Recommended:1442025-03-12
Elacestrant, an estrogen receptor antagonist developed by the Italian company Menarini, was first approved for marketing by the U.S. FDA on January 27, 2023. Subsequently, it has b···【more】
Article source:Lucius LaosRelease date:2026-03-16Recommended:44
Elacestrant is an estrogen receptor antagonist developed by the Italian company Menarini. It received its first approval from the U.S. Food and Drug Administration (FDA) on January···【more】
Article source:Lucius LaosRelease date:2026-03-16Recommended:47
Elacestrant is suitable for the treatment of specific types of breast cancer.【more】
Article source:Lucius LaosRelease date:2026-01-05Recommended:69
LuciusVersionofElacestrant:DosageandAdministration,Indications,PrecautionsIndicationsElacestrant is an estrogen receptor antagonist indicated for:The treatment of postmenopausal wo···【more】
Article source:Lucius LaosRelease date:2025-12-03Recommended:144

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: